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Identification of Novel Mutations Causing Familial
Primary Congenital Glaucoma in Indian Pedigrees
Shirly G. Panicker,1 Aramati B. M. Reddy,1 Anil K. Mandal,1 Niyaz Ahmed,2
Hampapathalu A. Nagarajaram,2 Seyed E. Hasnain,2 and Dorairajan Balasubramanian1
PURPOSE. To determine the possible molecular genetic defect
underlying primary congenital glaucoma (PCG) in India and to
identify the pathogenic mutations causing this childhood blind-
ness.
METHODS. Twenty-two members of five clinically well-charac-
terized consanguineous families were studied. The primary
candidate gene CYP1B1 was amplified from genomic DNA,
sequenced, and analyzed in control subjects and patients to
identify the disease-causing mutations.
RESULTS. Five distinct mutations were identified in the coding
region of CYP1B1 in eight patients of five PCG-affected fami-
lies, of which three mutations are novel. These include a novel
homozygous frameshift, compound heterozygous missense,
and other known mutations. One family showed pseudodomi-
nance, whereas others were autosomal recessive with full
penetrance. In contrast to all known CYP1B1 mutations, the
newly identified frameshift is of special significance, because
all functional motifs are missing. This, therefore, represents a
rare example of a natural functional CYP1B1 knockout, result-
ing in a null allele (both patients are blind).
CONCLUSIONS. The molecular mechanism leading to the devel-
opment of PCG is unknown. Because CYP1B1 knockout mice
did not show a glaucoma phenotype, the functional knockout
identified in this study has important implications in elucidat-
ing the pathogenesis of PCG. Further understanding of how
this molecular defect leads to PCG could influence the devel-
opment of specific therapies. This is the first study to describe
the molecular basis of PCG from the Indian subcontinent and
has profound and multiple clinical implications in diagnosis,
genetic counseling, genotype-phenotype correlations and
prognosis. Hence, it is a step forward in preventing this dev-
astating childhood blindness. (Invest Ophthalmol Vis Sci.
2002;43:1358–1366)
The glaucomas, a heterogeneous group of optic neuropa-thies, if untreated, lead to optic nerve atrophy and perma-
nent loss of vision. Glaucoma accounts for 15% of blindness
worldwide.1 One severe form of glaucoma, which occurs at
birth or in early infancy (up to 3 years of age), is primary
congenital glaucoma (PCG), which is mainly inherited as an
autosomal recessive disorder. In contrast to a prevalence of
1:10,000 in the West,2 prevalence is as high as 1:1250 among
the Romany population of Slovakia,3 and 1:2500 in the Middle
East,4 where inbreeding occurs, suggesting a genetic etiology.
In the Indian state of Andhra Pradesh, the prevalence is 1:3300,
and the disease accounts for 4.2% of all childhood blindness.5,6
However, the genetic defect of this disorder was unknown,
and this prompted us to undertake the investigation.
Genetic linkage studies by Sarfarazi et al.7 and Akarsu et al.8
mapped PCG to two different loci, GLC3A (at 2p21)7 and
GLC3B (at 1p36),8 in which mutations within the CYP1B1
gene (encoding the cytochrome P450 enzyme at GLC3A) were
associated with the disease.9 Several CYP1B1 mutations in
various ethnic backgrounds have been implicated in the patho-
genesis.10–20 To determine the possible genetic defect under-
lying PCG in India, molecular analyses of five families were
undertaken, and the CYP1B1 coding region was screened for
mutations. Herein, we describe the pathogenic mutations
(some of which are novel), including a natural CYP1B1 func-
tional knockout, their genotype–phenotype correlations, struc-
ture–function relationship, and the simple diagnostic methods
developed for identifying these mutations.
METHODS
Clinical Evaluation and Patient Selection
The study protocol adhered to the tenets of the Declaration of Helsinki.
After providing informed consent, five consanguineous PCG families
were recruited for the study. These families were selected because all
family members were available for the investigation. Patients and
family members were evaluated by a glaucoma specialist (AKM) and
were followed up for 10 years. The clinical data of the patients are
described in Table 1. Ophthalmic examinations included slit lamp
biomicroscopy, gonioscopy, measurement of intraocular pressure
(IOP), and perimetry in some cases. Clinical manifestations included
elevated IOP, enlargement of the globe, edema, opacification of the
cornea with rupture of the Descemet’s membrane, thinning of anterior
sclera and atrophy of the iris, anomalously deep anterior chamber,
photophobia, blepharospasm, and excessive tearing.
Mutation Screening and Sequence Analyses
Because mutations in CYP1B1 are the predominant cause of PCG, the
entire coding region (1.6 kb organized in exons II and III)21 was
screened for mutations. Only these two exons were screened, because
both contain the mutational hot spots of the gene and all pathogenic
mutations reported so far are harbored in exons II and III. DNA was
extracted from the peripheral leukocytes of patients, family members
and control subjects. Using three sets of overlapping primers, the
CYP1B1 gene was amplified from patients and control subjects (Table
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2). Amplicons were sequenced directly, and the patient and control
sequences were compared to identify all mutations. The primers used
were as follows: set I (1 forward [F]/1 reverse [R], 786 bp),12 set II
(2F/2R, 648 bp),22 and set III (3F/3R, 885 bp).12 All PCRs were per-
formed for only 30 cycles, and conditions for sets I and II were as
reported earlier12; conditions for set III are given in Table 2. Twenty-
five- to 50-L polymerase chain reactions (PCR) were performed with
the following: 50 to 100 ng genomic DNA, 1 PCR buffer with 1.5 to
2.0 mM MgCl2, 200 M dNTPs, 0.5 M of each primer, and 1 U Taq
polymerase (Bangalore Genei, Bangalore, India), with or without 10%
dimethyl sulfoxide (DMSO). Primer sets I and II had 10% DMSO and 1.5
mM MgCl2, whereas set III had only 2.0 mM MgCl2. The same sets of
primers were used for PCR and bidirectional sequencing. The three
amplicons were purified (pre-PCR sequencing kit; USB, Cleveland,
OH), terminator cycle sequencing was performed (BigDye kit; PE-
Applied Biosystems, Foster City, CA), and sequencing reactions were
performed on an automated DNA sequencer (ABI model 377; PE-
Applied Biosystems).
PCR-Restriction Fragment Length Polymorphism
Analyses and Cosegregation of Mutant Alleles
with Disease Phenotype
In all cases, mutations resulted in either loss or gain of recognition sites
(Table 2). For determining the cosegregation of mutant alleles with
disease phenotype in the family, the respective fragment harboring the
mutation was amplified from all family members, and an aliquot of
amplicons was digested with the corresponding restriction enzymes
(Table 2; MBI Fermentas, Vilnius, Lithuania). The fragments were
separated on 8% polyacrylamide gel, stained with ethidium bromide
and visualized to distinguish the wild type and mutant alleles. Seventy
volunteer donors without history of eye disorders served as control
subjects.
RESULTS
Identification of Pathogenic Mutations
Novel Frameshift Mutation and Functional Null Allele.
In family PCG4 (an uncle-to-niece marriage) two patients
showed a homozygous insertion (Figs. 1A, 1B; Table 2) of a
nucleotide A at cDNA position 376 (376insA). This novel mu-
tation, not previously reported,10–20 resulted in a frameshift
that truncated the open reading frame (ORF) by creating a
premature stop codon (TGA), 636 bp downstream from this
insertion. Consequently, a truncated 222-amino-acid (aa) pro-
tein missing 321 aa from the C terminus was generated (Fig.
1C). This also abolished the restriction site Eco130I in exon II.
Both the wild-type and the mutant proteins contained just 10
aa at the N terminus, which is similar in both, and the frame-
shift eliminated all CYP1B1 domains, resulting in a functional
null allele. All unaffected members in family PCG4 were het-
erozygous for this mutation (Fig. 2A).
Novel Compound Heterozygous Mutations and
Pseudodominance. In another family (PCG1; marriage be-
tween first cousins), parent-to-child transmission of the disease
was noticed. This is an interesting pedigree in which the
daughter (proband) and mother were affected with bilateral
PCG and the father was a normal carrier (Fig. 3A). Two affected
generations showed varying severity and manifestations. The
mother showed asymmetric manifestation (left eye blind, right
eye mildly affected), whereas the proband displayed a uniform
milder manifestation in both eyes. The proband had a novel
compound heterozygous missense mutation (Table 2) within
exon II. The first mutation (Fig. 3B) was a C3T substitution at
923 bp, resulting in a proline-to-leucine change at aa 193
(P193L) and a gain of the restriction site Eco81I. The second TA
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mutation (Fig. 3B) was a G3A substitution at 959 bp, resulting
in replacement of glutamic acid with lysine at aa 229 (E229K)
and loss of restriction site Eam1104I (Fig. 2C).
The maternal grandfather (I.1), mother (II.1), and proband
(III.1) in PCG1 were heterozygous for 923C3T, whereas the
father (II.2), proband (III.1), and unaffected sibling (III.2) were
heterozygous for 959G3A (Figs. 3A, 3B). Consistent with the
recessive mode of inheritance, the proband had inherited two
heterozygous mutant alleles (III.1), one from each parent.
Sequence analysis of the affected mother (II.1) revealed only
one mutant allele (Fig. 3A). The presumed second mutant allele
has yet to be identified. For recessive disease to develop, the
patient should have two mutant alleles either in the heterozy-
gous or homozygous state. The unaffected sibling (III.2) had
inherited one paternal heterozygous mutant allele, and it may
be that she also inherited the unknown mutant allele from the
mother. Repeated sequencing of the CYP1B1 coding region in
the mother (II.1) and unaffected sibling (III.2) failed to identify
the other heterozygous mutation, suggesting its possible pres-
ence either in the promoter or in some other regulatory region.
Although we presume that this unaffected sibling (III.2) had
inherited two mutant alleles, at 8 years of age she had not yet
shown any symptoms of glaucoma and hence she could be
considered as a glaucoma suspect. The first mutation (P193L)
maps to a region highly conserved among various types of
cytochromes, whereas the E229K mutation is conserved only
among the CYP1B1 types (Fig. 4). Screening of 70 control
subjects by PCR-restriction fragment length polymorphism
(RFLP) not only confirmed the absence of this compound
heterozygous mutation in the normal population, but also
supports that it is likely to be pathogenic. However, a few
control subjects (12.8%) were heterozygous for the 923C3T
(E229K) mutation, but none for the 959G3A (P193L) muta-
tion.
Homozygous Missense Mutations. Three families were
identified with two known homozygous missense muta-
tions10,15,23: two with the R368H homozygous mutation and
one with the G61E homozygous mutation (Table 2). Both are
highly conserved across various members of the cytochrome
P450 superfamily (Fig. 4). These mutations were found to
segregate with four patients (families PCG2 and PCG11, one
patient each; PCG6, two patients) in three unrelated consan-
guineous families (PCG2 and PCG6, first-cousin marriage;
PCG11, uncle-to-niece marriage). Consistent with recessive in-
heritance, mutant alleles segregated with disease phenotypes
in all families.
Patients in families PCG2 and PCG6 showed the same ho-
mozygous mutation: G3A substitution at 1449 bp. This re-
sulted in a arginine-to-histidine change at aa 368 (R368H) in
CYP1B1 and a loss of restriction site TaaI in exon III (Table 2).
In PCG11, substitution of a nucleotide G3A at cDNA position
528 resulted in a glycine-to-glutamic acid replacement at aa 61
(G61E) of CYP1B1 and a gain of the restriction site TaqI in
exon II (Table 2).
Nonpathogenic CYP1B1 Single Nucleotide
Polymorphisms
In addition to pathogenic mutations five other single nucleo-
tide polymorphisms (SNPs; Table 3) were identified in the less
conserved region of CYP1B1. Because PCG6 had two different
homozygous missense mutations, the highly conserved residue
(R368H, reported earlier)15 was considered to be a pathogenic
mutation, whereas the less conserved one (G184S) was taken
to be a novel polymorphism (Fig. 4).
Structural Implications of Mutant Proteins
It is interesting to note that, of the four amino acid mutations
(excluding insertion mutation), three occur in the less-con-
served N-terminal domain of the protein. An alignment of the
amino acid sequence with a homologue of known three-dimen-
sional structure (Protein Data Bank [PDB] code: 1DT6) re-
vealed that all the mutation sites are away from the heme-
binding pocket and therefore probably do not affect directly
the binding of the heme. However, these sites seem to be
important in maintaining the structural integrity of the protein.
The conserved glycine residue at position aa 61 is in a left-hand
helical conformation and is in a very unique position where the
peptide chain takes a sharp turn. Position aa 193 forms the
N-capping region of the helix (aa 173–210) and is most suited
for proline, which is also highly conserved. Any amino acid
change at this position may disrupt the helical structure. The
same is probably true for the position E229, which is in the
middle of the helix (aa 218–234). R368 is probably less impor-
tant structurally, because the site is in the loop region, which
is on the surface of the protein and is probably necessary for
protein–protein interactions.
Our examination of the translated product of the frameshift
mutation (376insA) revealed that the amino acid sequence of
FIGURE 1. Electropherogram of the sense strand of genomic DNA
from the proband in family PCG4, showing a novel homozygous
frameshift mutation. Note the homozygous insertion of a nucleotide A
(376insA) in the mutant allele of the proband (B), which is absent in
the control (A). The mutation, which is underlined and shown by an
arrow, results in premature termination at aa 223. The comparison of
normal versus all truncated protein known in exon II is also shown (C).
() Sequences that are common between normal and wild-type pro-
tein; () mutant protein. The length of truncated protein and its
references are shown on the right.
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the new ORF does not show an appreciable match with any of
the known protein sequences in the PDB. A secondary struc-
ture prediction of the sequence showed that the translated
product is mostly made of coiled regions.
Genotype–Phenotype Correlations
Correlation between genotype and phenotype based on this
study was evident from a comparison of the different muta-
tions associated with varying manifestations and prognoses of
the disease (Table 4). The PCG phenotypes associated with
various mutations showed varying severity and manifestations.
In some cases, there was asymmetric manifestation between
eyes of the patients (mother in family PCG1), whereas
the same mutation (R368H) exhibited interfamily (families
PCG2 and -6) as well as intrafamily (family PCG6) variability
(Tables 1, 4).
DISCUSSION
This is the first genetic study from India to describe the mo-
lecular defect underlying the PCG phenotype and demon-
strates the direct association of the CYP1B1 mutations with
this devastating childhood blindness.22 Unknown developmen-
tal defects of the trabecular meshwork and anterior chamber
angle of the eye cause this disorder.10,21,24 In our investigation
of five consanguineous PCG-affected Indian families, five
pathogenic mutations (including three novel ones) were iden-
tified in eight affected members. These include a novel ho-
mozygous frameshift mutation resulting in a functional null
allele and compound heterozygous missense and known mis-
sense mutations (Table 2). That all are disease-causing muta-
tions is shown by the fact that all mutant alleles cosegregate
with the disease phenotype and are absent in the normal
population and that the mutated residues are highly conserved
across various members of the cytochrome P450 superfamily
(Fig. 4). In addition, five SNPs were found in the affected
families. These were either observed in the general population
and/or were found to affect poorly conserved amino acid
residues exclusively (Fig. 4). This study also indicates that
CYP1B1 could be the predominant cause of PCG in the Indian
ethnic background, because all families analyzed so far have
had mutations in this gene.
Pseudodominant inheritance was seen in one family,
whereas all others showed autosomal recessive inheritance
with full penetrance. All patients inherited two mutant alleles,
whereas unaffected members were heterozygous (carriers) for
a single mutant allele segregating in that particular family,
except in the pseudodominant family (Fig. 2).
FIGURE 2. PCR-RFLP analyses of the
cosegregation of different mutations
with disease phenotypes. Filled
squares and circles: Affected individ-
uals; arrow: probands; dot in open
symbol: carriers; double line: con-
sanguinity. DNA molecular weight
marker (lane M) in base pairs (left);
allele sizes (right); control (lane C);
mutant allele(s) (arrowheads). Re-
striction site changes and mutations
(nucleotide as well as amino acid
changes) are shown at the bottom of
each panel. (✽) Sample for analysis
unavailable. (A) Wild-type allele am-
plification and restriction digestion
of amplicon from control DNA gen-
erated 384- and 158-bp fragments
(lane C). Mutation abolishes the
Eco130I site. In heterozygous indi-
viduals (carriers) in addition to the
wild-type allele, a mutant allele of
542 bp was present. In the disease
phenotype (homozygous) only a mu-
tant allele of 542 bp was evident. (B)
C3T substitution in PCG1 results in
a gain of an Eco811 site, which is
evident from the cleavage of the
648-bp fragment (lane C) into 523-bp
and 125-bp fragments. In carriers, in
addition to the wild-type allele a mu-
tant allele of 648 bp was present. (C)
Restriction digestion of the wild-type
allele in the control generated 359-
and 229-bp (lane C) fragments and
abolished the Eam1104I site. In car-
riers, in addition to the wild-type al-
lele 588, mutant alleles of 359 and
229 bp were present. (D) Restriction
digestion of the wild-type allele in
the control showing undigested frag-
ment of 627 bp (lane C). Mutation creates a TaqI site. In carriers, in addition to the wild type allele, mutant alleles of 318 and 309 bp were present.
In the disease phenotype (homozygous) only mutant alleles of 318 and 309 bp were present. (E, F) Restriction digestion of wild type allele in the
control generated 507- and 200-bp fragments (lane C). Mutation creates a TaaI site. In carriers, in addition to the wild-type allele, a mutant allele
of 352 bp was present. In the disease phenotype (homozygous) only mutant alleles of 507 and 352 bp were present.
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Of all mutations identified herein, the frameshift mutation
resulted in the most severe phenotype. Only the first 10 aa of
the 543-aa CYP1B1 protein remain unchanged by the frame-
shift, whereas the remainder of the protein was replaced by an
out-of-frame polypeptide of 222 aa. Despite maximum medical
and prompt surgical treatments, both patients in family PCG4
exhibited a most devastating phenotype and were blind
(Fig. 5).
In all PCG-pseudodominant families reported so far,10,12,15
the affected parent has been homozygous and the other a
normal carrier; but analysis of the present pseudodominant
family (PCG1) indicates that the affected parent (II.1) is a
compound heterozygote. Moreover, an interesting observation
is that probably there are three compound heterozygous indi-
viduals (II.1, III.1, and III.2) in this family, all segregating with
different combinations of mutant alleles (Fig. 3) with varying
expression, of which one exhibits normal phenotype (unaf-
fected sibling [III.2]—a glaucoma suspect). The exact age of
onset of the disease in this case was difficult to ascertain
because the affected status of the mother (II.1) was revealed
through her daughter (the proband [III.1]). The presence of
Haab’s striae in the left eye of the affected mother (Table 1)
suggests that she had PCG in that eye before 3 years of age,
whereas the right eye had late-onset PCG. An asymmetric
manifestation of PCG was seen in the affected mother (the left
eye became blind at 21 years, whereas IOP in the right eye is
under control with medication).
The mother had glaucoma diagnosed at age 30 (Table 1) and
had ocular features indicating that disease may have begun in
one eye before age 3. However, because the second CYP1B1
mutation has not been identified in the mother (II.1), and this
missing allele, as passed on to her 8-year-old daughter (III.2),
has resulted in a normal phenotype (Fig. 3A), this seems to be
a complex situation, for which various plausible explanations
FIGURE 3. (A) Pedigree showing seg-
regation of alleles in PCG1 family. (✽)
Grandmother’s DNA was not available
for analysis. Heterozygous alleles are
denoted by a slash separating wild
type in uppercase letters and mutant
residues in lowercase letters. (B) Elec-
tropherogram of the sense strand of
various members of family PCG1. Res-
idues are numbered based on cDNA
sequence. Arrows: mutated bases.
FIGURE 4. Multiple sequence alignment of various members of the cytochrome P450 superfamily. Bold letters with asterisk and shading:
conserved residues (when mutated) causing PCG phenotype. †Polymorphic residues. Right: sequence accession numbers. The human CYP1B1
sequence is underlined.
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can be considered: (1) The dramatic phenotypic variability
observed between the two eyes of the affected mother is
possibly the consequence of an as yet unknown mutation
within the promoter region (perhaps a promoter deletion), and
may indicate that CYP1B1 is a dosage-sensitive gene. (2) The
mother may simply be a carrier of congenital glaucoma who
happens also to have an early-onset form of glaucoma caused
by mutation at another locus or glaucoma of a nongenetic
origin. (3) It may be possible that heterozygosity for the
923C3T mutation causes late-onset disease, although to our
knowledge there are no reported instances of development of
late-onset disease in carriers of the CYP1B1 mutation. (4) If the
mother has a new mutation and is mosaic for the mutation, she
could have one eye more affected than the other, because of
unequal representation of the defect in the two eyes. It is
possible that she has an unaffected child who inherited that
chromosome, because of the absence of the mutation in the
germ line. Although various roles for CYP1B1 in eye develop-
ment have been proposed recently,23 it is tempting to specu-
late that the likely role of CYP1B1 is in the detoxification or
elimination of a toxic metabolite, which may be harmful to the
normal development of the eye.
Previous studies have indicated that the G61E and R368H
mutations are not fully penetrant in Saudi families,10,15
whereas in these Indian families, both are fully penetrant.
R368H, reported earlier,15 maps to helix K, which is one of the
highly conserved core structures (CCSs). This homozygous
mutation seen in three patients of two unrelated families
(PCG2 and PCG6) shows a very severe phenotype, in either
one or both eyes. The CCSs are suspected to be involved in
proper protein folding and in active heme binding.23 There-
fore, any homozygous impairment of this domain could lead to
a severe phenotype. The other highly conserved G61E muta-
tion12 is adjacent to the N-terminal proline-rich region of
CYP1B1 and is also likely to affect the proper protein function
and result in disease manifestation. The proline-proline-glycine-
proline motif may serve to join the membrane-binding N ter-
minus to the globular region of the P450 protein.9,10,15,23
Because the anterior chamber angle in humans has under-
gone some very recent evolutionary changes, this may be a
problem in using animal models, especially the CYP1B1 knock-
out mice, for studying PCG’s pathogenesis.23 Typical trabecu-
lar meshwork can be found only in humans and higher
primates, whereas lower species have only a reticular mesh-
work.24 Although it may be difficult to extrapolate the findings
obtained from the CYP1B1 null mice, the phenotype obtained
in such mice need not be the same as that of the functional
CYP1B1 knockout identified in the present study. This view is
in fact substantiated by a study, wherein it was demonstrated
that CYP1B1 null mice did not show any obvious blindness or
evidence of glaucoma, as assessed by standard behavioral com-
parisons with wild-type mice in their response to light and
dark.25 Furthermore, a frequent observation in various knock-
out studies is that the phenotypes do not transfer identically
across species.
The information derived from this study has both basic and
clinical relevance. Genetic counseling can be provided to at-
risk families that will aid in the prevention of PCG-related
blindness. The characterization of CYP1B1 and the spectrum
of mutations with evidence of pathogenicity and high pen-
TABLE 3. Single Nucleotide Polymorphisms Identified in PCG-Affected Families
Pedigree Intron/Exon
Sequence Change
(genomic/cDNA position in bp)
Codon
Change
Mutation
Type Novel* or Reported
PCG1, PCG2, PCG6, and PCG11 Intron I 3793 T3C (13 bp)† Not applicable — Refs. 12, 15
PCG4 Exon II 488 C3G R48G Missense Refs. 12, 15, 19, 18
PCG6 Exon II 896 G3A G184S Missense Novel*
PCG2 Exon III 1640 G3C V432L Missense Refs. 9, 12, 15, 18, 19
PCG1 Exon III 1693 T3C D449D Silent Refs. 12, 15, 19, 18
* Reported for the first time in this study.
† Indicates 13 bp upstream of ATG or genomic DNA position 3793 bp.
TABLE 4. Genotype/Phenotype Effect
Pedigree Mutation Laterality
Severity*
(OD; OS)
Prognosis
(OD; OS)
PCG4
Proband Ter@223 aa Bilateral OU very severe† OU very poor
Affected sibling Ter@223 aa Bilateral OU very severe† OU very poor
PCG11, proband G61E Bilateral OU mild OU good
PCG1
Proband P193L and E229K Bilateral OU mild OU good
Affected mother P193L‡ Bilateral with late onset OD OD normal OD good
OS very severe† OS very poor
PCG2 proband R368H Bilateral OD mild OD good
OS very severe OS very poor
PCG6
Proband R368H Bilateral OD mild OD good
OS very severe OS very poor
Affected sibling R368H Bilateral OU very severe OU very poor
* Severity of the disease is arbitrarily graded based on the corneal changes, IOP, cup-to-disc ratio, and last recorded visual acuity (20/20 is
normal; 20/20–20/40 is mild; 20/40–20/200 is severe; 20/200–PL is very severe; NPL is blind; see Table 1.
† Affected individual is blind.
‡ Second mutation in PCG1 mother is unknown.
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etrance could have profound clinical implications in the man-
agement of PCG. This will facilitate prenatal diagnosis for this
condition, which carries high life-long morbidity. Indeed, fur-
ther screening of probands using the simple, fast, and inexpen-
sive PCR-RFLP diagnostic methods developed in this study has
enabled us to rapidly identify similar mutations in several other
PCG-affected families (Reddy et al., manuscript in preparation).
However, further analysis of more families with PCG is needed
to determine the clinical correlation with the severity of the
disease, if any.
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